Lidoflazine
Chemical compound
- C08EX01 (WHO)
- 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
- 3416-26-0 Y
- 3926
- 3789 N
- J4ZHN3HBTE
- D04733 Y
- DTXSID6045377
- Interactive image
- CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
InChI
- InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36) N
- Key:ZBIAKUMOEKILTF-UHFFFAOYSA-N N
Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.
Physical properties
Solubility at room temperature
Extracted from[1]
Solvent | 0.01 N | 0.1 N | ||
% | pH | % | pH | |
Hydrochloric Acid | 0.4 | 3.0 | 0.7 | 1.9 |
Tartaric Acid | 0.3 | 3.1 | 1.0 | 2.5 |
Citric Acid | 0.3 | 3.1 | 0.5 | 2.5 |
Lactic Acid | 0.2 | 3.4 | 0.7 | 2.9 |
Acetic Acid | 0.1 | 3.5 | 0.4 | 3.8 |
References
- ^ a b Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. PMID 5944369.
Further reading
- Schaper WK, Xhonneux R, Jageneau AH (November 1965). "Stimulation of the coronary collateral circulation by lidoflazine (R 7904)". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 252 (1): 1–8. doi:10.1007/bf00246424. PMID 4222721. S2CID 31959581.
- v
- t
- e
Ion channel modulators
VGKCsTooltip Voltage-gated potassium channels |
| ||||
---|---|---|---|---|---|
IRKsTooltip Inwardly rectifying potassium channel |
| ||||
KCaTooltip Calcium-activated potassium channel |
| ||||
K2PsTooltip Tandem pore domain potassium channel |
|
VGSCsTooltip Voltage-gated sodium channels |
| ||||
---|---|---|---|---|---|
ENaCTooltip Epithelial sodium channel |
| ||||
ASICsTooltip Acid-sensing ion channel |
|
CaCCsTooltip Calcium-activated chloride channel |
| ||||
---|---|---|---|---|---|
CFTRTooltip Cystic fibrosis transmembrane conductance regulator |
| ||||
Unsorted |
|
TRPsTooltip Transient receptor potential channels |
|
---|---|
LGICsTooltip Ligand gated ion channels |
|
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
- ^ Zhou PZ, Babcock J, Liu LQ, Li M, Gao ZB (June 2011). "Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules". Acta Pharmacologica Sinica. 32 (6): 781–788. doi:10.1038/aps.2011.70. PMC 4085723. PMID 21623390.